Study of the Epidemiological, Clinical, Diagnostic, and Therapeutic Characteristics of Gastric Cancers in Algeria (ECLIPSE-CG)

March 25, 2026 updated by: Société Algérienne de Formation et Recherche en Oncologie

The goal of this observational study is to describe the demographic, epidemiological, clinical, and outcome characteristics of patients with gastric cancer.

It also aims to analyze the diagnostic approaches and management strategies used in the care of these patients in Algeria.

Study Overview

Status

Recruiting

Conditions

Detailed Description

This is a non-interventional, observational, descriptive, cross-sectional clinical study with both prospective and retrospective data collection. It aims to describe the demographic, epidemiological, clinical, and outcome characteristics of approximately 1,000 patients with histologically confirmed gastric cancer in Algeria, and to analyze diagnostic and treatment practices.

Data will be collected from medical records and brief patient interviews (≈30 minutes). All information will be anonymized and used exclusively for research purposes.

Study Type

Observational

Enrollment (Estimated)

1000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Algeria
    • Algeria
      • Algiers, Algeria, Algeria, 16000
      • Algiers, Algeria, Algeria, 16000

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Patients with histologically confirmed gastric cancer, followed in the participating oncology departments.

Description

Inclusion Criteria:

  • Patients aged 19 years and older
  • Histologically confirmed diagnosis of gastric cancer
  • Patients followed in the participating oncology departments
  • Informed consent obtained

Non Inclusion Criteria:

  • Histological types other than carcinoma (e.g., GIST, lymphoma, sarcoma, etc.).
  • Secondary gastric tumors
  • Participation in an interventional study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Demographic characteristics of patients with gastric cancer in Algeria
Time Frame: At Baseline ( Initial visit )
The patient's demographic profile will include age (years) and sex. Body Mass Index (BMI) will be calculated using weight (kg) and height (m) according to the formula BMI = weight / height² (kg/m²).
At Baseline ( Initial visit )
Sociological characteristics of patients with gastric cancer in Algeria
Time Frame: At Baseline ( Initial visit )
The patient's sociological profile will be described as a composite variable : Education level (primary, secondary, university, other), Profession (employed, unemployed, retired, student, other), Place of residence (current residence; urban or rural), Origin (wilaya of birth/origin)
At Baseline ( Initial visit )
Epidemiological characteristics of patients with gastric cancer in Algeria.
Time Frame: At Baseline (Initial Visit)
Frequency (%) of epidemiological risk factors including family history of cancer, Helicobacter pylori infection, smoking status, alcohol consumption, dietary habits, and exposure to chemical substances.
At Baseline (Initial Visit)
Clinical characteristics of patients with gastric cancer in Algeria.
Time Frame: At Basline ( Initial Visit)
Distribution of patients according to initial symptoms, tumor localization, histological characteristics, biomarker expression, presence of metastases, and tumor stage according to the AJCC classification.
At Basline ( Initial Visit)
Evolutionary characteristics of patients with gastric cancer.
Time Frame: At Baseline ( Initial Visit)
Distribution of treatment modalities including surgery (palliative or curative) and chemotherapy (adjuvant or treatment lines), as well as treatment response, complications, disease-free survival (DFS), and duration of response.
At Baseline ( Initial Visit)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Diagnostic modalities in patients with gastric cancer in Algeria
Time Frame: At Basline (Initial Visit)
Proportion (%) of patients diagnosed using endoscopy, biopsy, or imaging, and median time to diagnosis (days) defined as the interval between first reported symptom and confirmed diagnosis.
At Basline (Initial Visit)
Therapeutic management modalities
Time Frame: At Baseline (Initial Visit)
Proportion (%) of patients receiving surgery, chemotherapy, targeted therapy, immunotherapy, or palliative care, median time from confirmed diagnosis to initiation of first treatment (days), and proportion of patients with documented post-treatment follow-up.
At Baseline (Initial Visit)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Société Algérienne de Formation et Recherche en Oncologie

Collaborators

Bristol-Myers Squibb
ES Clinical Research

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 5, 2025

Primary Completion (Estimated)

August 5, 2026

Study Completion (Estimated)

August 5, 2026

Study Registration Dates

First Submitted

September 4, 2025

First Submitted That Met QC Criteria

March 16, 2026

First Posted (Actual)

March 18, 2026

Study Record Updates

Last Update Posted (Actual)

March 27, 2026

Last Update Submitted That Met QC Criteria

March 25, 2026

Last Verified

September 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • SAFRO 02.001

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Gastric Cancer

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Congo

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe